Skip to content

Study · Randomized controlled trial · n = 20 · 2016

5 results

Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.

Ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Drent ML, Diamant M, IJzerman RG

Diabetes care17 Aug 2015Cited by 83 (Europe PMC)

PMID26283736 (opens in a new tab)DOI10.2337/dc15-0772 (opens in a new tab)PepBankPUB-26283736
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, HbA1c fell more with liraglutide than with insulin glargine after 12 weeks.

    In plain wordsIn obese people with type 2 diabetes, liraglutide lowered HbA1c more than insulin glargine did.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change after 12 weeks
    Study

    n = 20

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 12 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.7%
    liraglutide
    HbA1c change
    −0.2%
    insulin glargine

    Source sentences

    Summary
    After 12 weeks, the decrease in HbA1c was larger with liraglutide versus insulin glargine (Δ-0.7% vs. -0.2%, P < 0.001).
    2 context sentences
    Summary · context
    We performed a randomized crossover study in obese patients with type 2 diabetes (n = 20, mean age 59.3 ± 4.1 years, mean BMI 32 ± 4.7 kg/m(2)), consisting of two periods of 12-week treatment with either liraglutide 1.8 mg or insulin glargine.
    Summary · context
    Using functional MRI, we determined the effects of treatment on CNS responses to viewing food pictures in the fasted condition and 30 min after meal intake.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, body weight fell by 3.3 kg with liraglutide, while it changed by 0.8 kg with insulin glargine.

    In plain wordsIn obese people with type 2 diabetes, body weight fell more with liraglutide than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change after 12 weeks
    Study

    n = 20

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · 12 weeksAs given in this study (human).

    Measurements

    body weight change
    −3.3 kg
    liraglutide
    body weight change
    0.8 kg
    insulin glargine

    Source sentences

    Summary
    Body weight decreased during liraglutide versus insulin glargine (Δ-3.3 kg vs. 0.8 kg, P < 0.001).
    2 context sentences
    Summary · context
    We performed a randomized crossover study in obese patients with type 2 diabetes (n = 20, mean age 59.3 ± 4.1 years, mean BMI 32 ± 4.7 kg/m(2)), consisting of two periods of 12-week treatment with either liraglutide 1.8 mg or insulin glargine.
    Summary · context
    Using functional MRI, we determined the effects of treatment on CNS responses to viewing food pictures in the fasted condition and 30 min after meal intake.
  3. 03HumanRandomized controlled trialMechanism

    In obese patients with type 2 diabetes, after 10 days liraglutide decreased brain responses to food pictures in the insula and putamen versus insulin glargine.

    In plain wordsIn obese people with type 2 diabetes, after 10 days liraglutide reduced brain responses to food pictures more than insulin glargine did.

    Peptide
    Liraglutide
    Outcome
    DecreaseCNS responses to food pictures after 10 days
    Study

    n = 20

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.8 mg · 10 daysAs given in this study (human).

    Source sentences

    Summary
    After 10 days, patients treated with liraglutide, compared with insulin glargine, showed decreased responses to food pictures in insula and putamen (P ≤ 0.02).
    2 context sentences
    Summary · context
    We performed a randomized crossover study in obese patients with type 2 diabetes (n = 20, mean age 59.3 ± 4.1 years, mean BMI 32 ± 4.7 kg/m(2)), consisting of two periods of 12-week treatment with either liraglutide 1.8 mg or insulin glargine.
    Summary · context
    Using functional MRI, we determined the effects of treatment on CNS responses to viewing food pictures in the fasted condition and 30 min after meal intake.
  4. 04HumanRandomized controlled trialMechanism

    In obese patients with type 2 diabetes, liraglutide enhanced the satiating effect of meal intake on brain responses in the putamen and amygdala versus insulin glargine.

    In plain wordsIn obese people with type 2 diabetes, liraglutide strengthened the brain's fullness response after a meal in two regions, compared with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreaseSatiating effect of meal intake on CNS responses
    Study

    n = 20

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.8 mg · 10 daysAs given in this study (human).

    Source sentences

    Summary
    In addition, liraglutide enhanced the satiating effect of meal intake on responses in putamen and amygdala (P ≤ 0.05).
    2 context sentences
    Summary · context
    We performed a randomized crossover study in obese patients with type 2 diabetes (n = 20, mean age 59.3 ± 4.1 years, mean BMI 32 ± 4.7 kg/m(2)), consisting of two periods of 12-week treatment with either liraglutide 1.8 mg or insulin glargine.
    Summary · context
    Using functional MRI, we determined the effects of treatment on CNS responses to viewing food pictures in the fasted condition and 30 min after meal intake.
  5. 05HumanRandomized controlled trialMechanism

    In obese patients with type 2 diabetes, brain responses to food pictures did not differ between liraglutide and insulin glargine after 12 weeks.

    In plain wordsIn obese people with type 2 diabetes, after 12 weeks liraglutide and insulin glargine no longer differed in brain responses to food pictures.

    Peptide
    Liraglutide
    Outcome
    No significant changeCNS responses to food pictures after 12 weeks
    Study

    n = 20

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.8 mg · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Differences between liraglutide and insulin glargine were not observed after 12 weeks.
    2 context sentences
    Summary · context
    We performed a randomized crossover study in obese patients with type 2 diabetes (n = 20, mean age 59.3 ± 4.1 years, mean BMI 32 ± 4.7 kg/m(2)), consisting of two periods of 12-week treatment with either liraglutide 1.8 mg or insulin glargine.
    Summary · context
    Using functional MRI, we determined the effects of treatment on CNS responses to viewing food pictures in the fasted condition and 30 min after meal intake.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.